DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.310 +0.180 (+2.21%)

Delayed Quote Updated: 10:49 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021

August 05, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 28, 2021

From DiaMedica Therapeutics

Via Business Wire

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

July 15, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗

July 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

58 Biggest Movers From Yesterday ↗

June 30, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....

Via Benzinga

Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge ↗

June 29, 2021

Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65. The U.S. has the highest...

Via Benzinga

Topics Stocks

Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher ↗

June 29, 2021

Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63. The U.S. has the...

Via Benzinga

Topics Stocks

35 Stocks Moving In Tuesday's Mid-Day Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results ↗

June 29, 2021

Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59. The U.S. has...

Via Benzinga

Topics Stocks

DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients ↗

June 29, 2021

DiaMedica Therapeutics Inc (NASDAQ: DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). The...

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD

June 29, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke ↗

May 17, 2021

The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of...

Via Benzinga

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

May 17, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

May 05, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

April 28, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

April 22, 2021

From DiaMedica Therapeutics Inc.

Via Business Wire

51 Biggest Movers From Friday ↗

April 12, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and...

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

April 09, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 09, 2021

Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 32.67% to $67.0 during Friday's pre-market session. The company's market cap stands at $860.7...

Via Benzinga

30 Stocks Moving in Friday's Pre-Market Session ↗

April 09, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) rose 32.3% to $19.00 in pre-market trading after the company reported a worldwide licensing agreement with Pfizer to develop and...

Via Benzinga

10 Stocks Moving In Thursday's After-Hours Session ↗

April 08, 2021

Gainers FuboTV (NYSE: FUBO) shares are trading higher after the company announced it acquired exclusive streaming rights to the Qatar World Cup 2022 Qualifying matches of South...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 08, 2021

Gainers DiaMedica Therapeutics (NASDAQ:DMAC) shares increased by 6.17% to $9.98 during Thursday's after-market session. DiaMedica Therapeutics's trading volume hit 12.0K...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.